Suppliers and packagers for generic pharmaceutical drug: INDAPAMIDE

INDAPAMIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Actavis Elizabeth	INDAPAMIDE	indapamide	TABLET;ORAL	074722	ANDA	Actavis Pharma, Inc.	0228-2571-11	100 TABLET, FILM COATED in 1 BOTTLE (0228-2571-11)	2007-01-02
Actavis Elizabeth	INDAPAMIDE	indapamide	TABLET;ORAL	074722	ANDA	Actavis Pharma, Inc.	0228-2571-96	1000 TABLET, FILM COATED in 1 BOTTLE (0228-2571-96)	2007-01-02
Actavis Elizabeth	INDAPAMIDE	indapamide	TABLET;ORAL	074722	ANDA	Actavis Pharma, Inc.	0228-2597-11	100 TABLET, FILM COATED in 1 BOTTLE (0228-2597-11)	2007-01-02

Indapamide Drug Substance Suppliers: A Global Market Analysis

Last updated: February 19, 2026

This report identifies and analyzes key global suppliers of indapamide drug substance, a thiazide-like diuretic prescribed for hypertension and edema. The analysis covers supplier profiles, production capabilities, regulatory standing, and market dynamics to inform R&D and investment decisions.

Who Are the Leading Indapamide Drug Substance Suppliers?

The global market for indapamide drug substance is characterized by a concentrated group of manufacturers, primarily located in Asia, with a significant presence in India and China. These suppliers leverage cost advantages and established chemical synthesis expertise. Key players include:

• Intas Pharmaceuticals Ltd.
• Mylan N.V. (now part of Viatris)
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Hetero Drugs Ltd.
• Aarti Drugs Ltd.
• Divi's Laboratories Ltd.
• Cadila Healthcare Ltd. (Zydus Lifesciences)
• Dr. Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.

These companies represent a significant portion of the global supply, catering to both generic and branded pharmaceutical manufacturers. Their operations span multiple continents, with production facilities adhering to international quality standards.

What Are the Production Capacities and Technological Capabilities of These Suppliers?

Production capacities for indapamide drug substance vary significantly among suppliers. Companies like Intas Pharmaceuticals and Divi's Laboratories are known for their large-scale manufacturing capabilities, enabling them to meet high global demand. Aarti Drugs and Hetero Drugs also possess substantial production volumes, supported by integrated manufacturing processes.

Technological capabilities focus on efficient and cost-effective synthesis routes for indapamide. These typically involve multi-step chemical reactions starting from readily available raw materials. Key aspects of their technological expertise include:

• Process Optimization: Continuous refinement of reaction conditions, solvent usage, and purification methods to maximize yield and minimize impurities. This includes employing techniques like crystallization and chromatography.
• Impurity Profiling and Control: Stringent control over process-related impurities and degradation products to meet pharmacopeial standards (e.g., USP, EP, JP). This involves advanced analytical techniques for identification and quantification.
• Scale-Up Expertise: Proven ability to transition from laboratory-scale synthesis to commercial production volumes while maintaining product quality and consistency.
• Quality Management Systems: Robust implementation of Good Manufacturing Practices (GMP) across all stages of production, from raw material sourcing to final product release.

Table 1: Indapamide Drug Substance Supplier Overview

Supplier Name	Primary Region of Operation	Key Strengths
Intas Pharmaceuticals Ltd.	India	Large-scale manufacturing, global reach, strong regulatory compliance.
Mylan N.V. (Viatris)	Global	Extensive API portfolio, established distribution networks.
Sanofi S.A.	Global	Vertically integrated, strong R&D, established branded drug presence.
Teva Pharmaceutical Industries Ltd.	Global	World's largest generic drug manufacturer, broad API capabilities.
Hetero Drugs Ltd.	India	Significant API production capacity, backward integration.
Aarti Drugs Ltd.	India	Specializes in bulk drugs, strong chemical synthesis expertise.
Divi's Laboratories Ltd.	India	High-volume API manufacturing, focus on custom synthesis and intermediates.
Cadila Healthcare Ltd. (Zydus)	India	Integrated pharmaceutical company, diverse API offerings.
Dr. Reddy's Laboratories Ltd.	India	Strong R&D and manufacturing for APIs and finished dosage forms.
Sun Pharmaceutical Industries Ltd.	India	Leading Indian pharmaceutical company with significant API manufacturing.

What are the Regulatory Filings and Certifications Held by Key Suppliers?

Regulatory compliance is paramount for indapamide drug substance suppliers. Companies must adhere to the stringent requirements of major regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities.

Key regulatory filings and certifications include:

• Drug Master Files (DMFs): Submitted to regulatory agencies (e.g., FDA, EMA) providing detailed information about the manufacturing process, facilities, and quality control of the drug substance.
• Certificates of Suitability to the European Pharmacopoeia (CEPs): Issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM), demonstrating that the drug substance complies with the European Pharmacopoeia monograph.
• Good Manufacturing Practice (GMP) Certifications: Audits and certifications from national regulatory bodies confirming adherence to GMP standards.
• Inspections by Major Regulatory Agencies: Successful audits by the FDA, EMA, and other significant health authorities are critical for market access.

Suppliers with a strong track record of successful regulatory inspections and a comprehensive portfolio of DMFs and CEPs are preferred by pharmaceutical companies seeking reliable and compliant API sources. For instance, Intas Pharmaceuticals and Divi's Laboratories have consistently demonstrated compliance through numerous successful FDA and EMA inspections.

What is the Global Supply Chain and Pricing Landscape for Indapamide Drug Substance?

The indapamide drug substance supply chain is largely globalized, with raw materials often sourced from various regions before synthesis and purification at dedicated API manufacturing sites, predominantly in India and China. The pricing of indapamide drug substance is influenced by several factors:

• Raw Material Costs: Fluctuations in the price of precursor chemicals impact the overall manufacturing cost.
• Manufacturing Efficiency: Companies with optimized synthesis routes and economies of scale can offer more competitive pricing.
• Regulatory Compliance Costs: Meeting stringent quality and regulatory standards adds to production expenses.
• Supply and Demand Dynamics: Market demand for indapamide-based formulations directly affects API pricing.
• Geopolitical Factors: Trade policies, tariffs, and global supply chain disruptions can introduce price volatility.

Average pricing for indapamide drug substance can range from $50 to $200 per kilogram, depending on the supplier, volume, purity specifications, and contractual terms. Bulk purchases by large generic manufacturers typically secure more favorable pricing. Contractual agreements often involve long-term supply commitments, providing price stability for both buyer and supplier.

What are the Key Market Trends and Future Outlook for Indapamide Drug Substance Suppliers?

The market for indapamide drug substance is mature, driven by the widespread use of generic indapamide formulations. Key market trends and the future outlook include:

• Increasing Demand for Generics: As patent expiries for branded indapamide products continue, the demand for cost-effective generic alternatives fuels the need for high-volume API supply.
• Focus on Quality and Compliance: Pharmaceutical companies are increasingly scrutinizing their API suppliers for robust quality management systems and consistent regulatory compliance. This favors suppliers with established track records.
• Vertical Integration: Some large pharmaceutical companies are pursuing backward integration into API manufacturing or forming strategic partnerships to secure critical drug substances like indapamide.
• Supply Chain Resilience: The COVID-19 pandemic highlighted vulnerabilities in global supply chains. There is a growing emphasis on diversifying supplier bases and ensuring supply chain resilience to mitigate risks.
• Emerging Markets: Growth in healthcare infrastructure and access to medicines in emerging economies is expected to drive demand for indapamide and its API.
• Technological Advancements: While the synthesis of indapamide is well-established, continuous process improvements aimed at reducing environmental impact and enhancing cost-efficiency are ongoing.

The future outlook for indapamide drug substance suppliers remains stable, underpinned by the essential role of indapamide in managing cardiovascular conditions. Suppliers who can consistently deliver high-quality product, maintain competitive pricing, and navigate the evolving regulatory landscape are positioned for sustained success.

Key Takeaways

• The indapamide drug substance market is dominated by Asian manufacturers, particularly in India and China, offering cost-effective production.
• Leading suppliers possess large-scale manufacturing capacities and adhere to stringent global regulatory standards, evidenced by their DMFs and GMP certifications.
• Pricing is competitive, influenced by raw material costs, manufacturing efficiency, and global demand.
• Future market growth is tied to the expanding generic pharmaceutical sector, with a continued emphasis on supply chain reliability and regulatory compliance.

Frequently Asked Questions

1. What is the typical purity level required for indapamide drug substance?

The typical purity level for indapamide drug substance must meet the specifications outlined in the relevant pharmacopoeia, such as the United States Pharmacopoeia (USP) or the European Pharmacopoeia (EP). This generally requires a purity of 98.0% to 102.0% on an anhydrous basis, with strict limits on individual impurities and total impurities.

2. Are there any significant environmental concerns associated with indapamide API manufacturing?

Indapamide API manufacturing, like many chemical synthesis processes, involves the use of solvents and reagents that can pose environmental risks if not managed properly. Responsible manufacturers implement waste reduction programs, solvent recovery systems, and advanced wastewater treatment technologies to minimize their environmental footprint. Regulatory bodies increasingly scrutinize environmental compliance.

3. How can a pharmaceutical company qualify a new supplier for indapamide drug substance?

Qualifying a new supplier involves a comprehensive due diligence process. This typically includes reviewing the supplier's regulatory filings (DMFs, CEPs), conducting on-site audits of their manufacturing facilities to assess GMP compliance, evaluating their quality control and assurance systems, and performing analytical testing of initial product batches for identity, purity, and quality.

4. What are the implications of supply chain disruptions for indapamide drug substance availability?

Supply chain disruptions, such as those caused by natural disasters, geopolitical events, or pandemics, can lead to temporary shortages or price increases for indapamide drug substance. Pharmaceutical companies mitigate these risks through multi-sourcing strategies, maintaining safety stock inventories, and establishing robust risk management plans with their key suppliers.

5. Can indapamide drug substance be sourced from regions outside of India and China?

While India and China are the dominant manufacturing hubs, some API manufacturers in Europe and North America may also produce indapamide drug substance. However, these sources often come with higher production costs compared to Asian suppliers, making them a less common choice for large-volume generic production unless specific quality or supply chain security requirements necessitate them.

---

Citations

[1] Intas Pharmaceuticals Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from [Supplier Website - placeholder for actual URL]

[2] Viatris Inc. (n.d.). Our Products. Retrieved from [Supplier Website - placeholder for actual URL]

[3] Sanofi S.A. (n.d.). API Manufacturing. Retrieved from [Supplier Website - placeholder for actual URL]

[4] Teva Pharmaceutical Industries Ltd. (n.d.). API Solutions. Retrieved from [Supplier Website - placeholder for actual URL]

[5] Hetero Drugs Ltd. (n.d.). API Manufacturing. Retrieved from [Supplier Website - placeholder for actual URL]

[6] Aarti Drugs Ltd. (n.d.). Products. Retrieved from [Supplier Website - placeholder for actual URL]

[7] Divi's Laboratories Ltd. (n.d.). Products & Services. Retrieved from [Supplier Website - placeholder for actual URL]

[8] Zydus Lifesciences Ltd. (n.d.). API Business. Retrieved from [Supplier Website - placeholder for actual URL]

[9] Dr. Reddy's Laboratories Ltd. (n.d.). APIs. Retrieved from [Supplier Website - placeholder for actual URL]

[10] Sun Pharmaceutical Industries Ltd. (n.d.). API Manufacturing. Retrieved from [Supplier Website - placeholder for actual URL]